G protein couple receptors used as Drug target

Abstract

The G- Protein coupled receptors are the largest class of cell-surface receptors and are encoded by > 1000 genes in the human genome. G-protein coupled receptors represented by far the largest class of targets for modern drugs. The current thinking surrounding GPCR homo-oilgomerization, hetero- oilgomerization and shows how new models point towards unexplored avenues in the development of new therapies. Numerous diseases and disorders have been linked mutations and Polymorphisms in GPCRs. They are the targets of an increasingly large number of therapeutic agents. It has been estimated that 50% of all modern drugs and almost one-quarter of the top 200 best – sellingdrugs in 2000 modulate GPCR activity. For many other classes of receptors such as tyrosine – kinase, ligand induced oilgomerization has long been known to be the essential for signalling. The greatest challenge facing the pharmaceutical industry will be to integrate GPCR homo- and hetero- oilgomerization into the molecular models that are used in the development of novel and improved therapeutics. The incorporation of oilgomerization receptor models into strategies for GPCR drug discovery might result in better therapeutic agents that target these receptors.